CPA
ARIA

Cowen Prime Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Cowen Prime Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-950
Closed -$8K – 326
2015
Q1 		$8K Sell
950
-903
-49% -$6.68K ﹤0.01% 261
2014
Q4 		$13K Hold
1,853
– – 0.01% 253
2014
Q3 		$10K Sell
1,853
-950
-34% -$5.55K ﹤0.01% 254
2014
Q2 		$18K Hold
2,803
– – 0.01% 208
2014
Q1 		$23K Buy
2,803
+803
+40% +$6.25K 0.01% 203
2013
Q4 		$14K Buy
+2,000
New +$10.8K 0.01% 219

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Cowen Prime Advisors's ARIA Position: Q2 2015 in Review

Cowen Prime Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2015, closing a stake of 950 shares — an estimated $8K sold.

Cowen Prime Advisors first reported a position in ARIA in Q4 2013 and held it in 6 quarters. The position peaked at $23K in Q1 2014. 177 funds tracked by Wall St. Rank hold ARIA as of Q2 2015.

  • Cowen Prime Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Cowen Prime Advisors sold 950 Ariad Pharmaceuticals Inc shares in Q2 2015, an estimated $8K.
  • Cowen Prime Advisors first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 6 quarters.
  • Cowen Prime Advisors's Ariad Pharmaceuticals Inc position peaked at $23K in Q1 2014.
  • 177 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2015.

Based on Cowen Prime Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.